Botulinum toxin type A
BiologicalBotulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
Other names: AbobotulinumtoxinA (Dysport®)
NCT Number: NCT00447876
This study will investigate the hypothesis that the analgesic effect of a single injection of Dysport (200 MU) induces a significant reduction of symptoms in chronic cases of plantar fasciitis.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2 / Phase 3
Orthopedic Practice Biberburg, Berlin, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
Other names: AbobotulinumtoxinA (Dysport®)
0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
Time frame: Baseline and Week 6
The responder rate was defined as the percentage of patients whose pain score while moving during the last 48 hours, measured by means of a 10 cm Visual Analogue Scale (VAS, 0 = no pain, 10 = maximum pain) decreased by at least 50% at Week 6 as compared to baseline. Pain at movement is the cardinal symptom of plantar fasciitis and the 10 cm VAS is a reference method for the assessment of pain intensity.
Time frame: Baseline and Week 18
The Gerbershagen scale gives a global score ranging between I and III, with lower scores reflecting less impact of pain in terms of temporal, spatial aspects, drug taking behaviour and utilization of the health care system. The changes in Gerbershagen's global scores from baseline to Week 18 are reported as percentage of patients for each of the specified categories.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Assessments of the pain intensity while moving (maximum pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The changes from baseline, expressed as Pain Intensity Difference (PID) values at each indicated timepoint are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Assessments of the pain intensity while moving (maximum pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The PID values at each timepoint were determined by comparison to baseline, followed by calculation of the area under the curve (AUC) of PID as a function of time (i.e. SPID). The least square (LS) means of SPID, adjusted for the baseline value of pain while moving are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Assessments of the pain intensity while at rest (continuous pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The changes from baseline, expressed as PID values at each indicated timepoint are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Assessments of the pain intensity while at rest (continuous pain during the previous 48 hours) were performed by means of a 10 cm VAS (0 = no pain, 10 = maximum pain) at each visit. The PID values at each timepoint were determined by comparison to baseline, followed by calculation of the AUC of PID as a function of time (i.e. SPID). The LS means for SPID, adjusted for the baseline value of pain at rest are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
The maximum pain felt in the medial back foot was measured using an algometer. The pain threshold corresponded to the maximum pressure at which pain was still tolerated. Changes from baseline, expressed as pain threshold differences at each indicated timepoint are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Assessments of the pain threshold using an algometer (which was the pressure corresponding to the maximum tolerated pain) were performed at each visit. Pain threshold differences at each timepoint were determined by comparison to baseline, followed by calculation of the AUC of the pain threshold difference as a function of time. The LS means of AUC, adjusted for the baseline value of pain threshold are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Pressure pain in the medial back foot was measured using an algometer. Pressure threshold corresponded to the minimum pressure causing pain. The changes from baseline, expressed as pressure threshold differences at each indicated timepoint are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
Assessments of the pressure threshold using an algometer (which corresponded to the minimum pressure causing pain) were performed at each visit. Pressure threshold differences at each timepoint were determined by comparison to baseline, followed by calculation of the AUC of the pressure threshold difference as a function of time. The LS means of AUC, adjusted for the baseline value of pressure threshold are reported.
Time frame: Baseline and Week 18
Dorsal extension and plantar flexion of the affected foot were assessed at baseline and at Week 18. A ROM of approximately 70 degrees is considered to be normal. The LS means, adjusted for the baseline value are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
A global assessment of the patient's current condition relative to baseline was performed by the Investigator at each visit using 5 level scale: significantly better, slightly better, unchanged, slightly worse, significantly worse. The number of patients for each variable at each indicated timepoint are reported.
Time frame: Baseline and Weeks 2, 6, 10, 14 and 18
A global assessment of the patient's current condition relative to baseline was performed by the patient at each visit using a 5 level scale: significantly better, slightly better, unchanged, slightly worse, significantly worse. The number of patients for each variable at each indicated timepoint are reported.
Ipsen
Industry
Double-blind, Placebo-controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05868577
Chronic Plantar Fasciitis, Fasciitis
Winston-Salem, North Carolina, United States
View Trial DetailsNCT06712329
Chronic Plantar Fasciitis, Fasciitis
Ankara, çankaya, Turkey (Türkiye)
View Trial DetailsNCT06737445
Chronic Plantar Fasciitis, Fasciitis
Kars, Merkez, Turkey (Türkiye)
View Trial DetailsNCT06348017
Chronic Plantar Fasciitis, Control Group
Yozgat, Turkey (Türkiye)
View Trial Details